Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.

Détails

ID Serval
serval:BIB_9C822C4B4241
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
Périodique
Cancer immunology, immunotherapy
Auteur(s)
Schmid S., Mauti L.A., Friedlaender A., Blum V., Rothschild S.I., Bouchaab H., Frösch P., Britschgi C., König D., Wannesson L., Janthur W.D., Schär S., Demmer I., Addeo A., Jochum W., Früh M.
ISSN
1432-0851 (Electronic)
ISSN-L
0340-7004
Statut éditorial
Publié
Date de publication
08/2020
Peer-reviewed
Oui
Volume
69
Numéro
8
Pages
1605-1613
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Early clinical trials showed promising outcomes with immune-checkpoint inhibitors (ICI) in a subset of patients with relapsed small-cell lung carcinoma (SCLC). The aim of this retrospective analysis was to assess the efficacy and safety of ICI for relapsed SCLC in a real-world patient population.
Nine cancer centres in Switzerland contributed data to this cohort. Responses were assessed by the local investigators using standard RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were analysed by the Kaplan-Meier method. Associations between potential predictive markers and survival endpoints were probed by Cox proportional hazards.
Forty-five patients were included in the analysis. Median age was 63 years, 73% were males and 18% had an ECOG performance status (PS) ≥ 2. ICIs were given as second-line treatment in 60%. Twenty-four patients (53%) received ipilimumab with nivolumab. Twenty-eight patients (62%) had undergone irradiation (RT) prior to or during ICI. Overall response rate (ORR) was 29% and median PFS and OS were 2.3 and 6.5 months, respectively. Median duration of response was 9 months (95% CI 2.8-NA). Five patients maintained their response for > 6 months, all of them receiving combination treatment. There were no new safety signals.
This is the first report of "real-world" data on ICI in relapsed SCLC also including patients with poor PS. Promising durable responses were observed. No biological prognostic marker could be identified.
Mots-clé
Adult, Aged, Antibodies, Monoclonal, Humanized/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Tumor/analysis, Female, Follow-Up Studies, Humans, Immunotherapy/mortality, Ipilimumab/administration & dosage, Lung Neoplasms/drug therapy, Lung Neoplasms/immunology, Lung Neoplasms/mortality, Lung Neoplasms/pathology, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/immunology, Neoplasm Recurrence, Local/mortality, Neoplasm Recurrence, Local/pathology, Nivolumab/administration & dosage, Prognosis, Retrospective Studies, Small Cell Lung Carcinoma/drug therapy, Small Cell Lung Carcinoma/immunology, Small Cell Lung Carcinoma/mortality, Small Cell Lung Carcinoma/pathology, Survival Rate, Switzerland, Biomarker, Checkpoint inhibitor treatment, Outcome, Real-life cohort, SCLC
Pubmed
Web of science
Création de la notice
25/04/2020 18:34
Dernière modification de la notice
26/11/2020 6:24
Données d'usage